TooNiceStocks Initiates Coverage on BioSante Pharmaceuticals, Inc. Looming February 14th, 2012 FDA Decision with Elevated Interest

BioSante Pharmaceuticals is a development stage biotech company focusing on drugs for sexual health and oncology. TooNiceStocks research discovered the recent collapse in the company’s stock on December 14, 2011 from the day’s high of 2.60 to a low of 0.38 in after hours trading, have left many investors asking, "so what’s next for BioSante?" Since then, BioSante has slowly recovered somewhat, the stock is still trading at a much-reduced range of $.50, a substantial discount of roughly $52 million market cap compared to about $286 million before the news. However with one drug approved and another facing a regulatory decision in the form of a PDUFA on February 14th, 2012, smallcap investors are already gambling.

(PRWeb January 13, 2012)

Read the full story at

Pfizer Must Pay $45 Million in Prempro Cases, Pennsylvania Court Rules

Pfizer Inc. (PFE) must pay more than $45 million in damages to two women who blamed the company’s menopause drugs for their breast cancers, an appeals court ruled.

Pfizer Has Settled About Half of Prempro Cases, Adds to Reserve

Pfizer Inc. (PFE) , the world’s largest drugmaker, has settled almost half of the lawsuits over its menopause drugs and increased the funds set aside to resolve the cases, the company said in a regulatory filing.

Pfizer Settles Prempro Case That Led to $72.6 Million Award

Pfizer Inc. (PFE) , the world’s largest drugmaker, agreed to settle claims that its menopause drugs caused cancer in three women who won a $72.6 million jury award earlier this week, a lawyer said.

Settlement reached in menopause-drug case

On the eve of starting the punitive phase of a civil trial that already involved a jury award of $72.6 million, Pfizer Inc. settled a case with three women who developed breast cancer after taking one of the company’s menopause drugs.

Next Page »